Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USPSTF cervical cancer screening guidelines

This article was originally published in The Gray Sheet

Executive Summary

Evidence is insufficient to recommend "for or against" use of new screening technologies, including liquid-based cytology, as well as HPV DNA testing, as a primary screen, U.S. Preventive Services Task Force states in guidelines released Jan. 22. While sensitivity generally is increased for liquid-based cytology, more false-positives often result, making it "not clear whether the possible benefits, if any, would be large enough to justify the added costs." USPTF's recommendations on screening intervals and when to start and cease screening are in line with ACS guidelines released in December (1"The Gray Sheet" Jan. 6, 2002, p. 23)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT017816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel